Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zalsenertant tetraxetan lutetium Lu-177
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Zalsenertant tetraxetan lutetium Lu‑177 is a radioconjugate composed of the neurotensin receptor type 1 (NTR1) antagonist IPN01087 (also known as 3BP‑227), linked via the chelating agent dodecanetetraacetic acid (DOTA) to the beta-emitting radioisotope lutetium Lu‑177. Upon administration, it binds to NTR1 expressed on certain tumor cells, particularly in ductal pancreatic adenocarcinoma. After binding and internalization, it delivers a cytotoxic dose of beta radiation specifically to NTR1-expressing cells, resulting in targeted antineoplastic activity and enabling imaging during PET/CT scans. The drug is being developed for use as both a therapeutic and diagnostic agent in oncology[1][4][8].
- Other names
- zalsenertant tetraxetan lutetium lu‑177lutetium lu‑177 zalsenertant tetraxetan
02
Targets
NTR1 (Nitroreductase-1)
Beyond the preview
Go deeper on zalsenertant tetraxetan lutetium Lu-177.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zalsenertant tetraxetan lutetium Lu-177.